ClinicalTrials.Veeva

Menu

Working Toward the Advancement of Recovery Using Modulated Therapeutic Hyperthermia (WARMTH) in Sepsis - Pilot

N

Nicholas M Mohr

Status

Withdrawn

Conditions

Sepsis

Treatments

Other: Multimodal therapeutic warming w/ esophageal d/c
Other: Multimodal therapeutic warming w/ conductive d/c

Study type

Interventional

Funder types

Other

Identifiers

NCT04961151
H202104263

Details and patient eligibility

About

The purpose of this pilot study is to demonstrate the ability to warm critically ill patients with sepsis to a target temperature of 39°C

Full description

Participants with sepsis and without fever will be warmed with surface (forced air and conductive wraps) and core (esophageal) warming, and will have the warming devices placed in the ICU. The warming devices will remain in place until the study is completed (36 hours). The heat exchangers will be set to attain a patient target temperature of 39°C as rapidly as possible, after which the forced-air (non-servo) system will be removed, and the conductive system heat exchanger (powering the water blankets and esophageal device, both of which are servo-controlled) will be set to maintain patient temperature at 39°C for the duration of the study period.

Once goal temperature has been achieved for 2 consecutive hours, the forced air warming device will be discontinued. Patients will be randomized at this point to Group 1, in which esophageal warming will be discontinued first or to Group 2, in which external conductive warming will be discontinued first.

All patients will have usual standard of care labs, vital signs, and imaging for patients undergoing mechanical ventilation in the ICU. For the duration of the 36-hour intervention, patient vital signs, including blood pressure, heart rate, respiratory rate, and vasopressor requirements will be monitored and recorded every 6 hours. Core temperature will be measured and recorded hourly.

Patient's clinical status and outcome will be reviewed in the medical chart 7 days after study completion.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients above the age of 18 years old.
  • Patients with sepsis diagnosed within 48 hours of enrollment. For the purpose of this protocol, sepsis onset is defined as administration of intravenous antibiotics in a patient that the treating critical care physician feels is ill from sepsis.
  • All qualifying patients must have a sequential organ failure assessment (SOFA) score of 2 or greater at the time of enrollment.
  • Patients requiring mechanical ventilation with an expected duration of mechanical ventilation of >= 2 days.
  • Patient maximum baseline documented temperature (within previous 24 hours) < 38.3°C.

Exclusion criteria

  • Patients without legally authorized representative able to provide informed consent.
  • Patients with contraindication to core warming using an esophageal core warming device, surface warming using conductive heat transfer, and forced air warmer.
  • Patients known to be pregnant.
  • Patients with <40 kg of body mass.
  • Patients with comfort care only status.
  • Patients with contraindications to hyperthermia treatment (acute stroke, acute traumatic brain injury, acute spinal cord injury, post-cardiac arrest, multiple sclerosis, or sickle cell disease).
  • Expected continuous dialysis within 48 hours after enrollment.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

0 participants in 2 patient groups

Conductive Wrap Warming
Experimental group
Description:
Esophageal warming will be discontinued first
Treatment:
Other: Multimodal therapeutic warming w/ esophageal d/c
Esophageal Warming
Experimental group
Description:
Conductive wraps will be discontinued first
Treatment:
Other: Multimodal therapeutic warming w/ conductive d/c

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems